Escherichia Coli Infections · Journal article

Escherichia coli outer membrane vesicles: Bacterial virulence, antibiotic resistance, host interactions, and applications in biomedical platforms.

Virulence · July 28, 2026

Hypothesis-Generating Why this matters to you Expert discussion

Raises a question worth testing. It does not answer one.

AI Summary

This is a comprehensive narrative review of E. coli outer membrane vesicles (OMVs), synthesizing knowledge of their biogenesis, composition, roles in virulence and antibiotic resistance, immune modulation, and potential biotechnological applications in vaccines, drug delivery, and tumor therapy. The review identifies OMVs as a promising platform for intervention but does not present original clinical trial data or definitive evidence that would change current practice.

What was studied

Narrative review. E. coli (both pathogenic and probiotic strains); infections affect women, the elderly, and immunocompromised individuals..

Key findings

E. coli OMVs are spherical nanostructures (20–400 nm diameter) enriched with bioactive components including proteins, lipopolysaccharides, phospholipids, toxins, and genetic material. OMVs play roles in delivery of virulence factors, biofilm formation, dissemination of antibiotic resistance, nutrient transport, and host-pathogen immune interactions. Extended-spectrum β-lactamase (ESBL)-producing and fluoroquinolone-resistant E. coli strains are listed by WHO as critical priority pathogens, with prevalence of ST131 lineages among drug-resistant isolates reaching 50–70%.

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

This review identifies E. coli OMVs as a potential platform for novel vaccine development, antimicrobial adjuvant delivery, and resistance modulation, but readers should recognize that most applications remain exploratory and require further clinical translation. The public health context of multidrug-resistant E. coli—particularly ESBL-producing and ST131 strains—motivates urgent research, but this review does not present validated clinical interventions.

Plain-language summary

This is a narrative review synthesizing existing literature on E. coli OMV biology, mechanisms, and potential applications; it raises research questions and identifies translational opportunities rather than reporting original experimental results or definitive clinical evidence.

Study design

As stated by the source record.

MethodsNarrative review

Reported figures

Quoted from the source exactly as published.

OMV diameter range20 to 400 nm

Prevalence of ST131 lineages among drug-resistant E. coli isolates50–70%

Clinical bottom line

Caveats

No original experimental data or clinical trial results reported; synthesis of existing literature only.
Translational applications (vaccines, drug delivery, tumor therapy) are described as putative or in-development; clinical efficacy not demonstrated in this source.
Specific mechanism of how OMVs disseminate antibiotic resistance genes is identified as a knowledge gap rather than resolved.
No quantitative systematic review, meta-analysis, or formal evidence grading methodology applied.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Review article; no primary experimental design or trial structure.

Directness

limited

Discusses putative mechanisms and applications; translational potential not yet clinically validated.

Consistency

insufficient

Synthesis of multiple prior studies; internal consistency of evidence not explicitly assessed.

Risk of bias

insufficient

Narrative review; no systematic methodology or bias assessment described.

Sample adequacy

insufficient

Literature review; not applicable to primary data collection.

Source abstract

Escherichia coli is a clinically significant Gram-negative pathogen, and the emergence of multidrug-resistant and highly virulent strains poses a grave threat to public health. Outer membrane vesicles (OMVs) are spherical nanostructures secreted by Gram-negative bacteria and composed of the outer membrane and a suite of encapsulated bioactive components, including proteins, lipopolysaccharides, and nucleic acids. Research indicates that OMVs play pivotal roles in pathogenic mechanisms, antimicrobial resistance transmission, and host-pathogen interactions. This review systematically elucidates the biogenesis mechanisms and molecular composition of E. coli OMVs while thoroughly examining their core biological functions in virulence, resistance, and immune modulation. Additionally, this review evaluates the translational potential of OMVs in vaccine development, biomolecular delivery, and tumor therapy. In summary, a comprehensive understanding of the biological properties and functions of E. coli OMVs is crucial for developing innovative OMV-based strategies for infection control, diagnosis, and therapy, thereby providing valuable directions for future research.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Bo YanWenqiang GuoYujin WangSiyi CaiQingwen LiEscherichia Coli InfectionsYafang Ding